Document Detail

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
MedLine Citation:
PMID:  23838677     Owner:  NLM     Status:  In-Data-Review    
Approximately 75% of patients with breast cancer present hormone receptor-positive tumors. This subtype of breast cancer initially shows a high overall response rate to hormonal treatments. However, resistance eventually develops, resulting in tumor progression. The PI3K/Akt/mTOR pathway regulates several cellular functions in cancer such as cell growth, survival, and proliferation. In addition, a high activation level of the PI3K/Akt/mTOR pathway is related to resistance to conventional chemotherapy and hormone therapy. The mTOR inhibitor everolimus, in combination with hormonal treatments, has led to excellent results in progression-free survival in patients with metastatic breast cancer resistant to hormone therapies. Therefore, everolimus has entered the National Comprehensive Cancer Network (NCCN) guidelines 2012 and its combination with exemestane was approved recently by the US Food and Drug Administration and the European Medicines Agency. This is the first time that a drug will have been approved for the restoration of hormone sensitivity in breast cancer.
Eva Ciruelos; Hernán Cortes-Funes; Ismael Ghanem; Luis Manso; Carlos Arteaga
Related Documents :
376127 - Current status of experimental chemical carcinogenesis and its applications to human ca...
24395247 - Targeting of mcl-1 kills myc-driven mouse and human lymphomas even when they bear mutat...
19589097 - Immunomodulatory effects of pteridium aquilinum on natural killer cell activity and sel...
23087147 - Modulation of ghrelin axis influences the growth of colonic and prostatic cancer cells ...
17507797 - Pkc delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic c...
19363467 - Adenovirus-based virotherapy enabled by cellular yb-1 expression in vitro and in vivo.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  24     ISSN:  1473-5741     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-07-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  769-80     Citation Subset:  IM    
aDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain bDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma ce...
Next Document:  Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin ...